Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 17, 2014

 

 

Infinity Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   000-31141   33-0655706

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

780 Memorial Drive, Cambridge, MA   02139
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 453-1000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

At our Annual Meeting of stockholders held on June 17, 2014, our stockholders voted on three matters as follows:

 

1. The following nine nominees were elected to our Board of Directors to serve for a one-year term expiring at the 2015 annual meeting of stockholders:

 

     Votes For      Votes Against      Votes
Abstaining
     Broker
Non-Votes
 

José Baselga, M.D., Ph.D.

     37,174,573         37,434         14,272         4,378,617   

Jeffrey Berkowitz, J.D.

     36,900,288         311,719         14,272         4,378,617   

Anthony B. Evnin, Ph.D.

     37,178,950         35,357         11,972         4,378,617   

Gwen A. Fyfe, M.D.

     37,161,461         52,839         11,979         4,378,617   

Eric S. Lander, Ph.D.

     37,178,013         36,449         11,817         4,378,617   

Adelene Q. Perkins

     36,807,652         406,320         12,307         4,378,617   

Norman C. Selby

     36,230,706         983,101         12,472         4,378,617   

Ian F. Smith

     37,155,278         58,677         12,324         4,378,617   

Michael C. Venuti, Ph.D.

     36,879,433         335,029         11,817         4,378,617   

 

2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.

 

Votes For

    

Votes Against

    

Votes Abstaining

    

Broker Non-Votes

 
  30,200,184         6,906,213         119,882         4,378,617   

 

3. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the current fiscal year was ratified.

 

Votes For

    

Votes Against

    

Votes Abstaining

    

Broker Non-Votes

 
  41,522,953         69,047         12,896         —     


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    INFINITY PHARMACEUTICALS, INC.
Date: June 17, 2014     By:  

/s/ Lawrence E. Bloch

      Lawrence E. Bloch
      EVP, Chief Financial Officer & Chief Business Officer